[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566305":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":20,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"18F-FDG PET\u002FCT and PET\u002FMR, 68Ga-FAPI-04 PET\u002FCT and PET\u002FMR","EXPERIMENTAL","After patient enrollment, 68Ga-FAPI-04 PET\u002FCT and PET\u002FMR examinations are performed. Within 1 week before and after the examination, PET\u002FCT and PET\u002FMR is also performed in patients.",[13],"Diagnostic Test: 18F-FDG PET\u002FCT and PET\u002FMR scan, 68Ga-FAPI-04 PET\u002FCT and PET\u002FMR scan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-FDG PET\u002FCT and PET\u002FMR scan, 68Ga-FAPI-04 PET\u002FCT and PET\u002FMR scan","Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET\u002FCT and PET\u002FMR scan after injection of 0.02 to 0.04 mCi\u002FKg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET\u002FCT and PET\u002FMR is completed.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhaoxia huang, B.S.","CONTACT","86+18929673449","1261152761@qq.com",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhaoxia Huang, B.S.",{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100566305","application-of-petmri-in-the-evaluation-of-the-efficacy-of-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-100566305",false,"NCT06653452","Application of PET\u002FMRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* (1) Age 18-75 years old; (2) ECOG score 0-2; (3) Pathologically confirmed as rectal adenocarcinoma; (4) The lower edge of the tumor is within 12cm from the anal edge; (5) Clinically staged as cT3-4N0M0 or cTanyN+M0; (6) Untreated patients who have not received radiotherapy, chemotherapy, and surgery, etc.; (7) Good liver and kidney function, can tolerate radiotherapy and surgery; (8) Patients and their families can understand the research plan, voluntarily participate in this research and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) ECOG score \\> 2; (2) Patients with multiple primary colorectal cancers; (3) Patients with a history of other malignant tumors within the past 5 years (except for cured basal cell carcinoma, cervical carcinoma in situ, surgically treated localized prostate cancer, or surgically removed breast ductal carcinoma in situ); (4) Patients with intestinal obstruction, intestinal perforation, gastrointestinal bleeding, and other emergencies requiring emergency surgery; (5) Pregnant or lactating women; (6) Patients with a history of severe mental illness, immune diseases, and hormone medication; (7) Patients with contraindications for MRI, PET examination, radiotherapy, immunotherapy, or surgical treatment; (8) Patients who have participated in other clinical studies within the last 3 months; (9) Any other conditions deemed unsuitable for inclusion by the researcher.","ALL","18 Years","75 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60],"NA","This study plans to include LARC patients receiving neoadjuvant therapy at this center, conducting PET\u002FCT and PET\u002FMR examinations before treatment, and PET\u002FMR examinations before surgery after neoadjuvant therapy. The changes in the lesion before and after treatment will be compared to evaluate the efficacy of neoadjuvant therapy, including: the relief situation of the rectal primary lesion ; lymph node metastasis; local infiltration around the tumor; peritoneal and other distant metastases , etc. The pathological relief diagnosed by surgical pathology is the gold standard, and the predictive efficacy of PET\u002FMR will be evaluated, comparing the advantages and disadvantages of 18F-FDG and 68Ga-FAPI PET\u002FMR, and comparing with traditional PET\u002FCT and rectal MRI to explore the value of PET\u002FMRI in predicting the efficacy of neoadjuvant therapy in LARC patients.",[63],"Locally Advanced Rectal Cancer (LARC)","2024-10-20",{"date":66,"type":67},"2024-10-22","ACTUAL",{"date":69,"type":67},"2024-07-01",{"date":71,"type":57},"2026-12-01",{"name":5,"class":6},1]